Código numérico 5311-14 Realizamos un estudio prospectivo, descriptivo, clínico-quirúrgico y aleatorio sobre 100 pacientes sometidos a abdominoplastia por 15 cirujanos distintos en el Hospital Salvador B.
BluePen Biomarkers provides a unique comprehensive multi-omics biomarker discovery and validation platform. We can quantify, integrate and analyze genomics, proteomics, metabolomics and lipidomics biomarkers, alongside clinical data, demographics and other phenotypic data. A unique bio-inspired signal processing analytic approach is used that has the proven ability to identify biomarkers in a wide variety of diseases. The resulting biomarkers can be used for diagnosis, prognosis, mechanistic studies and predicting treatment response, in contexts from core research through clinical trials. BluePen Biomarkers provides an additional groundbreaking research goal: identifying surrogate biomarkers from different modalities. This not only provides new biological insights, but enables least invasive, least-cost tests that meet or exceed the predictive quality of current tests.
INTRODUCTION:
Mucosal Schwann cell hamartoma (MSCH) is a benign mucosal lesion composed of spindle cells surrounding colonic crypts that can arise anywhere in the colon; usually in the rectosigmoid. Most reports of colonic MSCH are limited to case reports and two case series from tertiary-care academic settings involving 20 and 26 patients. Our retrospective study is the first to describe the characteristics of colorectal MSCH in a community gastroenterology practice.
METHODS:
We retrospectively identified patients with colorectal MSCH from the pathology database of a large, community gastroenterology practice of 157 physicians in Texas and Louisiana working at 24 outpatient centers. Data were collected from consecutive patients diagnosed with MSCH from 2015–2019. MSCH were confirmed by positive immunohistochemical staining for S-100. Historical data recorded included the endoscopic size and appearance of the polyps, location, indication(s) for colonoscopy, and patient age, sex, and race.
RESULTS:
184 colorectal MSCH from 179 patients were identified out of a total of 335,635 colon specimens. The median age of 59 years (range, 40–84). Sixty percent were female, 67% were White, and 25% were Black. The most common indications for colonoscopy were screening (55%), polyp surveillance (35%) and diagnostic (35%), which often overlapped. The polyps were described as sessile (65%), pedunculated (2%), mixed sessile/pedunculated (1.6%), and not specified (32%). The average size was 3.8 mm (range, 1–15 mm), and most were in the distal colon and rectum (77%) followed by transverse (11%) and proximal colon (10%). One MSCH was at an anastomosis and in one, the site was not specified.
CONCLUSION:
This large retrospective series is the first to describe colorectal MSCH in a community gastroenterology practice. Additionally, the large number of patients provides a better description of MSCH characteristics in comparison to prior small case series. MSCH were most commonly found during screening and surveillance colonoscopies in patients who were older, female and white. Most were located in the distal colon and rectum. Colorectal MSCHs are found infrequently at an approximate rate of 1 every 4 years by a community gastroenterologist, or 0.05% of colonoscopy biopsies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.